conv.

All stories
BusinessQuiet · 42h

Viking Therapeutics soars 39.5% on obesity drug maintenance trial data

VK2735 showed it could preserve up to 97% of weight loss on reduced dosing, challenging rivals Eli Lilly and Novo Nordisk.

newest coverage 1d agosummary written 1d ago7 pieces NewswiresGoogle News

What to know

  • VK2735 maintenance study showed patients on every-other-week dosing retained 97% of weight loss vs. 61% for placebo, with safety comparable to placebo—validating reduced dosing as a competitive advantage.
  • Stock surged 39.5% on the news, approaching 52-week highs, as investors and analysts see Viking challenging Eli Lilly and Novo Nordisk's obesity drug dominance through dosing flexibility and tolerability.
  • The company plans to explore oral formulations and has Phase 3 trials fully enrolled with additional oral Phase 3 initiation expected later in 2026, plus a strong $502M cash position to fund development.

“many investors had assumed Eli Lilly's tirzepatide would thoroughly dominate the GLP-1/GIP category, and that upcoming VK2735 maintenance data could establish adherence as the next major competitive battleground”

Oppenheimer, Equity research · Investing.com ↗

Viking Therapeutics Clinical-stage biopharmaceutical companyEli LillyEli Lilly Obesity drug competitorNovo Nordisk Obesity drug competitorOppenheimer Equity research analyst

Viking Therapeutics soars 39.5% on obesity drug maintenance trial data
Investing.com News

How it unfolded 1 development · click the chart to see its coverage articles

Peak 4 pieces in one hour at Sep 22, 9 AM; 7 pieces over 46 hours (7 articles) Sep 22, 6 AM — 2 pieces · 2 articles — Google News 1, Newswires 1Sep 22, 7 AM — 1 piece · 1 article — Newswires 1Sep 22, 8 AM — quietSep 22, 9 AM — 4 pieces · 4 articles — Google News 4Sep 22, 10 AM — quietSep 22, 11 AM — quietSep 22, 12 PM — quietSep 22, 1 PM — quietSep 22, 2 PM — quietSep 22, 3 PM — quietSep 22, 4 PM — quietSep 22, 5 PM — quietSep 22, 6 PM — quietSep 22, 7 PM — quietSep 22, 8 PM — quietSep 22, 9 PM — quietSep 22, 10 PM — quietSep 22, 11 PM — quietYesterday, 12 AM — quietYesterday, 1 AM — quietYesterday, 2 AM — quietYesterday, 3 AM — quietYesterday, 4 AM — quietYesterday, 5 AM — quietYesterday, 6 AM — quietYesterday, 7 AM — quietYesterday, 8 AM — quietYesterday, 9 AM — quietYesterday, 10 AM — quietYesterday, 11 AM — quietYesterday, 12 PM — quietYesterday, 1 PM — quietYesterday, 2 PM — quietYesterday, 3 PM — quietYesterday, 4 PM — quietYesterday, 5 PM — quietYesterday, 6 PM — quietYesterday, 7 PM — quietYesterday, 8 PM — quietYesterday, 9 PM — quietYesterday, 10 PM — quietYesterday, 11 PM — quietToday, 12 AM — quietToday, 1 AM — quietToday, 2 AM — quietToday, 3 AM — quiet 1
8 AM4 PMyesterday8 AM4 PMnow · 4:43 AM ET
  1. 1

    Viking stock surges 39.5% on maintenance data release

    VKTX surged 39.5% in pre-open trading, sending shares to $42 and approaching its 52-week high of $43.15, driven entirely by company-specific news rather than broader market movement.

    “In the 12-week maintenance phase, every-other-week dosing preserved up to 97% of prior weight loss and monthly dosing up to 90%, compared with 61% for placebo.”
    — Viking Therapeutics, Company announcement · source
  2. background

    Viking Therapeutics reports VK2735 maintenance study results — The San Diego-based biopharmaceutical company announced positive top-line results from the 12-week maintenance phase of VK2735, showing every-other-week dosing preserved up to 97% of prior weight loss and monthly dosing up to 90%, compared with 61% for placebo, with statistically significant separation and adverse event rates comparable to placebo.

Also covered reported alongside — the timeline has no entry for these yet

  1. 5 outlets Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.

    first by Investor's Business Daily, 1d ago · also Seeking Alpha, Investing.com News, Barron's, Moomoo

    5 more headlines